FIELD: chemistry; pharmaceutics.
SUBSTANCE: invention relates to biochemistry, particularly to a method of treating atopic dermatitis (AD) in an individual suffering moderate to severe or severe AD.
EFFECT: invention makes it possible to effectively treat atopic dermatitis (AD) in an individual having moderate to severe or severe AD, where the individual's age ranges from ≥ 6 years before < 12 years old.
25 cl, 5 dwg, 13 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATMENT OF ATOPIC DERMATITIS THROUGH INTRODUCTION OF IL-4R INHIBITOR | 2019 |
|
RU2801204C2 |
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
| METHODS FOR INCREASING VACCINE EFFICIENCY BY INJECTING IL-4R ANTAGONIST | 2017 |
|
RU2753869C2 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2713406C2 |
| METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | 2017 |
|
RU2759630C2 |
| METHODS FOR TREATMENT OR PREVENTION OF ASTHMA BY ADMINISTRATION OF IL-4R ANTAGONIST | 2018 |
|
RU2793745C2 |
| METHOD OF TREATING SKIN INFECTION BY ADMINISTERING ANTAGONIST IL-4R | 2015 |
|
RU2704999C2 |
| COMBINATION OF MONOCLONAL ANTIBODIES OF OX40 AGONIST AND 4-1BB AGONIST FOR CANCER TREATMENT | 2017 |
|
RU2748949C2 |
| TREATMENT OF IgE-MEDIATED ALLERGIC DISEASES | 2018 |
|
RU2800765C2 |
| NEMOLIZUMAB IN TREATMENT OF ATOPIC DERMATITIS WITH MODERATE TO SEVERE EXCORIATION | 2019 |
|
RU2758378C1 |
